Avdoralimab
- Generic Name
- Avdoralimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2226393-85-5
- Unique Ingredient Identifier
- DW4CE8MKS9
- Background
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
- Associated Conditions
- -
- Associated Therapies
- -
Bullous Pemphigoid - Executive Insights - Bullous Pemphigoid
Bullous pemphigoid (BP) affects elderly patients, often misdiagnosed, with no approved therapies in the US. Current treatments include off-label corticosteroids and immunomodulators. The BP pipeline includes advanced Phase III therapies like AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent, and Akari Therapeutics’ nomacopan. Unmet needs and market opportunities are significant due to lack of approved therapies and diagnostic biomarkers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath